Literature DB >> 33472029

A "Shot in the Arm" for Sickle Cell Disease.

Tim M Townes1.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33472029      PMCID: PMC7854344          DOI: 10.1016/j.ymthe.2021.01.009

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  4 in total

1.  Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.

Authors:  Erica B Esrick; Leslie E Lehmann; Alessandra Biffi; Maureen Achebe; Christian Brendel; Marioara F Ciuculescu; Heather Daley; Brenda MacKinnon; Emily Morris; Amy Federico; Daniela Abriss; Kari Boardman; Radia Khelladi; Kit Shaw; Helene Negre; Olivier Negre; Sarah Nikiforow; Jerome Ritz; Sung-Yun Pai; Wendy B London; Colleen Dansereau; Matthew M Heeney; Myriam Armant; John P Manis; David A Williams
Journal:  N Engl J Med       Date:  2020-12-05       Impact factor: 91.245

2.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Authors:  Haydar Frangoul; David Altshuler; M Domenica Cappellini; Yi-Shan Chen; Jennifer Domm; Brenda K Eustace; Juergen Foell; Josu de la Fuente; Stephan Grupp; Rupert Handgretinger; Tony W Ho; Antonis Kattamis; Andrew Kernytsky; Julie Lekstrom-Himes; Amanda M Li; Franco Locatelli; Markus Y Mapara; Mariane de Montalembert; Damiano Rondelli; Akshay Sharma; Sujit Sheth; Sandeep Soni; Martin H Steinberg; Donna Wall; Angela Yen; Selim Corbacioglu
Journal:  N Engl J Med       Date:  2020-12-05       Impact factor: 91.245

3.  Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial.

Authors:  Suryanarayan Somanathan; Roberto Calcedo; James M Wilson
Journal:  Mol Ther       Date:  2020-02-07       Impact factor: 11.454

4.  In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.

Authors:  Chang Li; Hongjie Wang; Aphrodite Georgakopoulou; Sucheol Gil; Evangelia Yannaki; André Lieber
Journal:  Mol Ther       Date:  2020-09-05       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.